{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T02:14:10Z","timestamp":1648606450176},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Background: Analytical error affects 2nd-trimester maternal serum screening for Down syndrome risk estimation. We analyzed the between-laboratory reproducibility of risk estimates from 2 laboratories.<\/jats:p>\n               <jats:p>Methods: Laboratory 1 used Bayer ACS180 immunoassays for \u03b1-fetoprotein (AFP) and human chorionic gonadotropin (hCG), Diagnostic Systems Laboratories (DSL) RIA for unconjugated estriol (uE3), and DSL enzyme immunoassay for inhibin-A (INH-A). Laboratory 2 used Beckman immunoassays for AFP, hCG, and uE3, and DSL enzyme immunoassay for INH-A. Analyte medians were separately established for each laboratory. We used the same computational algorithm for all risk calculations, and we used Monte Carlo methods for computer modeling.<\/jats:p>\n               <jats:p>Results: For 462 samples tested, risk figures from the 2 laboratories differed &amp;gt;2-fold for 44.7%, &amp;gt;5-fold for 7.1%, and &amp;gt;10-fold for 1.7%. Between-laboratory differences in analytes were greatest for uE3 and INH-A. The screen-positive rates were 9.3% for laboratory 1 and 11.5% for laboratory 2, with a significant difference in the patients identified as screen-positive vs screen-negative (McNemar test, P &amp;lt;0.001). Computer modeling confirmed the large between-laboratory risk differences.<\/jats:p>\n               <jats:p>Conclusion: Differences in performance of assays and laboratory procedures can have a large effect on patient-specific risks. Screening laboratories should minimize test imprecision and ensure that each assay performs in a manner similar to that assumed in the risk computational algorithm.<\/jats:p>","DOI":"10.1373\/clinchem.2006.068783","type":"journal-article","created":{"date-parts":[[2006,9,22]],"date-time":"2006-09-22T00:43:31Z","timestamp":1158885811000},"page":"2087-2094","source":"Crossref","is-referenced-by-count":5,"title":["Reproducibility of Risk Figures in 2nd-Trimester Maternal Serum Screening for Down Syndrome: Comparison of 2 Laboratories"],"prefix":"10.1093","volume":"52","author":[{"given":"Peter A","family":"Benn","sequence":"first","affiliation":[{"name":"Division of Human Genetics, Department of Genetics and Developmental Biology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory S","family":"Makowski","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, and Department of Obstetrics and Gynecology, University of Connecticut Health Center, Farmington, CT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James FX","family":"Egan","sequence":"first","affiliation":[{"name":"Division of Human Genetics, Department of Genetics and Developmental Biology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dave","family":"Wright","sequence":"first","affiliation":[{"name":"Department of Mathematics and Statistics, University of Plymouth, Plymouth, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2006,11,1]]},"reference":[{"key":"2020022801322505400_R1","doi-asserted-by":"crossref","unstructured":"Benn PA. Advances in prenatal screening for Down syndrome: I general principles and second trimester testing. Clin Chim Acta2002;323:1-16.","DOI":"10.1016\/S0009-8981(02)00186-9"},{"key":"2020022801322505400_R2","doi-asserted-by":"crossref","unstructured":"Benn PA. Advances in prenatal screening for Down syndrome: II first trimester testing and future directions. Clin Chim Acta2002;324:1-11.","DOI":"10.1016\/S0009-8981(02)00187-0"},{"key":"2020022801322505400_R3","unstructured":"Haddow JE, Palomaki GE. Prenatal screening for Down syndrome. Simpson JL Elias S eds. Essentials of Prenatal Diagnosis1993:185-220 Churchill Livingstone New York. ."},{"key":"2020022801322505400_R4","doi-asserted-by":"crossref","unstructured":"Reynolds TM, Penny MD. The mathematical basis of multivariate risk screening: with special reference to screening for Down syndrome associated pregnancy. Ann Clin Biochem1989;27:452-458.","DOI":"10.1177\/000456329002700506"},{"key":"2020022801322505400_R5","doi-asserted-by":"crossref","unstructured":"Cuckle H. Established markers in second trimester maternal serum. Early Hum Dev1996;47:S27-S29.","DOI":"10.1016\/S0378-3782(96)01814-2"},{"key":"2020022801322505400_R6","doi-asserted-by":"crossref","unstructured":"Wald NJ, Huttly WJ. Validation of risk estimation using the quadruple test in prenatal screening for Down syndrome. Prenat Diagn1999;19:1083-1084.","DOI":"10.1002\/(SICI)1097-0223(199911)19:11<1083::AID-PD686>3.0.CO;2-L"},{"key":"2020022801322505400_R7","doi-asserted-by":"crossref","unstructured":"Canick JA, Rish S. The accuracy of assigned risks in maternal serum screening. [Letter]Prenat Diagn1998;18:413-415.","DOI":"10.1002\/(SICI)1097-0223(199804)18:4<413::AID-PD260>3.0.CO;2-Y"},{"key":"2020022801322505400_R8","doi-asserted-by":"crossref","unstructured":"Benn PA, Collins R. Evaluation of analytical precision in maternal serum screening for Down syndrome. Ann Clin Biochem2001;38:28-36.","DOI":"10.1258\/0004563011900254"},{"key":"2020022801322505400_R9","doi-asserted-by":"crossref","unstructured":"Ellis AR. Antenatal screening for Down syndrome\u2014can we do better?. Ann Clin Biochem1993;30:421-424.","DOI":"10.1177\/000456329303000501"},{"key":"2020022801322505400_R10","unstructured":". College of Pathologists. FBR\/CAP Maternal Serum Screening Reports2005 College of Pathologists Northfield, IL. ."},{"key":"2020022801322505400_R11","doi-asserted-by":"crossref","unstructured":"Chen J, Heffley D, Beazoglou T, Benn PA. Utilization of amniocentesis by women screen-positive for Down syndrome by the second trimester triple test. Commun Genet2000;3:24-30.","DOI":"10.1159\/000016223"},{"key":"2020022801322505400_R12","doi-asserted-by":"crossref","unstructured":"Lambert-Messerlian GM, Eklund EE, Malone FD, Palomaki GE, Canick JA, D\u2019Alton ME. Stability of first- and second-trimester serum markers after storage and shipment. Prenat Diagn2006;26:17-21.","DOI":"10.1002\/pd.1326"},{"key":"2020022801322505400_R13","doi-asserted-by":"crossref","unstructured":"Wald NJ, Cuckle H, Brock JH, Peto R, Polani PE, Woodford FP. Maternal serum-alpha-fetoprotein measurement in antenatal screening for anencephaly and spina bifida in early pregnancy. Report of U.K. collaborative study on alpha-fetoprotein in relation to neural-tube defects. Lancet1977;1:1323-1332.","DOI":"10.1016\/S0140-6736(77)92549-1"},{"key":"2020022801322505400_R14","unstructured":"Haddow JE Palomaki GE Knight GJ Canick JA eds. Prenatal Screening for Major Fetal Disorders. Vol II. Down\u2019s Syndrome1998 Foundation for Blood Research Scarborough, ME. ."},{"key":"2020022801322505400_R15","doi-asserted-by":"crossref","unstructured":"Wald NJ, Cuckle HS, Densem JW, Nanchahal K, Royston P, Chard T, et al. Maternal serum screening for Down\u2019s syndrome in early pregnancy. BMJ1988;297:883-887.","DOI":"10.1136\/bmj.297.6653.883"},{"key":"2020022801322505400_R16","doi-asserted-by":"crossref","unstructured":"Watt HC, Wald NJ, Huttly WJ. The pattern of maternal serum inhibin-A concentrations in the second trimester of pregnancy. Prenat Diagn1998;18:846-848.","DOI":"10.1002\/(SICI)1097-0223(199808)18:8<846::AID-PD354>3.0.CO;2-P"},{"key":"2020022801322505400_R17","doi-asserted-by":"crossref","unstructured":"Wald NJ, Densem JW, Smith D, Klee GG. Four-marker serum screening for Down\u2019s syndrome. Prenat Diagn1994;14:707-716.","DOI":"10.1002\/pd.1970140810"},{"key":"2020022801322505400_R18","doi-asserted-by":"crossref","unstructured":"Wald NJ, Densem JW, George L, Muttukrishna S, Knight PG. Prenatal screening for Down\u2019s syndrome using inhibin-A as a serum marker. Prenat Diagn 1996;16:143\u201352. Erratum Prenat Diagn1997;17:285-290.","DOI":"10.1002\/(SICI)1097-0223(199703)17:3<285::AID-PD71>3.0.CO;2-A"},{"key":"2020022801322505400_R19","doi-asserted-by":"crossref","unstructured":"Wald NJ, Hackshaw AK, George LM. Assay precision of serum \u03b1 fetoprotein in antenatal screening for neural tube defects and Down\u2019s syndrome. J Med Screen2000;7:74-77.","DOI":"10.1136\/jms.7.2.74"},{"key":"2020022801322505400_R20","unstructured":"Cuckle HS. Updated modeling parameters for Down\u2019s syndrome screening. Balkan J Med Genet2003;6:101-107."},{"key":"2020022801322505400_R21","doi-asserted-by":"crossref","unstructured":"Cuckle H. Improving parameters for risk estimation in Down\u2019s syndrome screening. Prenat Diagn1995;15:1057-1065.","DOI":"10.1002\/pd.1970151111"},{"key":"2020022801322505400_R22","unstructured":". National Center for Health Statistics. Vital Statistics of the United States, 2000: Natility Data Set. CD ROM, Series 21, 142004 Hyattsville, MD. ."},{"key":"2020022801322505400_R23","doi-asserted-by":"crossref","unstructured":"Benn PA, Fang M, Egan JFX, Horne D, Collins R. Incorporation of Inhibin-A in second-trimester screening for Down syndrome. Obstet Gynecol2003;101:451-454.","DOI":"10.1097\/00006250-200303000-00008"},{"key":"2020022801322505400_R24","doi-asserted-by":"crossref","unstructured":"Benn PA, Wright D, Cuckle H. Practical strategies in contingent sequential screening for Down syndrome. Prenat Diagn2005;25:645-652.","DOI":"10.1002\/pd.1215"}],"container-title":["Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/52\/11\/2087\/32687724\/clinchem2087.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/52\/11\/2087\/32687724\/clinchem2087.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,28]],"date-time":"2020-02-28T06:35:20Z","timestamp":1582871720000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/clinchem\/article\/52\/11\/2087\/5626818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11,1]]},"references-count":24,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2006,11,1]]},"published-print":{"date-parts":[[2006,11,1]]}},"URL":"https:\/\/doi.org\/10.1373\/clinchem.2006.068783","relation":{},"ISSN":["0009-9147","1530-8561"],"issn-type":[{"value":"0009-9147","type":"print"},{"value":"1530-8561","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2006,11,1]]},"published":{"date-parts":[[2006,11,1]]}}}